Bedrijfsoverzicht
Summit Therapeutics Inc. is a biopharmaceutical entity dedicated to the discovery, development, and commercialization of medicinal therapies designed to be friendly toward patients, physicians, caregivers, and society. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, where its primary objective is the creation of innovative treatments for complex medical conditions. Summit Therapeutics employs a workforce of 265 individuals and holds a market capitalization of $15.25B, yet it reports N/A for its annual revenue figures. The substantial market capitalization of $15.25B relative to the unquantified revenue indicates a valuation heavily weighted toward the potential of its pipeline assets rather than current cash flow generation. This disparity suggests that the market values the company's future prospects regarding its lead candidate, ivonescimab, far more than its historical financial performance or current sales trajectory.
Financiële gezondheid
Summit Therapeutics reports N/A for revenue over the trailing twelve months and a net income of $-1,079,586,048, reflecting the typical early-stage dynamics of a clinical-stage biotechnology firm. The EBITDA stands at $-1,094,278,016, and the significant gap between the reported revenue of N/A and the massive net loss of $-1,079,586,048 reveals an intense cost structure driven by research and development expenditures rather than sales overhead. Despite the net loss, the company maintains a free cash flow of $84.08M, which provides a critical buffer for financial flexibility and operational continuity without relying on external financing. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard characteristic for biotech firms that have not yet achieved commercial product launch or where revenue does not cover direct costs yet. The balance sheet shows $713.45M in cash against $20.89M in debt, resulting in a debt-to-equity ratio of 3.17, which indicates a leveraged balance sheet structure common in capital-intensive industries but currently supported by strong liquidity. The current ratio of 9.87 demonstrates exceptional short-term liquidity, suggesting the company possesses nearly ten times the current assets necessary to cover its immediate liabilities. Furthermore, the Return on Equity is -206.1% and the Return on Assets is -115.3%, metrics that reveal the company is currently destroying shareholder value on a per-dollar basis due to heavy investment phases, though this is expected in the biotechnology sector.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the net loss, while the forward P/E is -16.83, implying that the market is pricing in a future earnings turnaround or that earnings are expected to be negative in the coming period. The price-to-book ratio is 23.14, indicating a significant market premium over the company's book value, which reflects high expectations for the success of its clinical candidates. The price-to-sales ratio is N/A and the EV/EBITDA is -13.30, suggesting that traditional multiple-based valuation models are not applicable given the lack of profitability and revenue. The stock has a 52-week high of $36.91 and a 52-week low of $13.83, with the current trading price situated in a wide range that reflects high volatility and uncertainty regarding the asset's clinical milestones. The beta value is -1.37, which is an anomalous negative figure indicating that the stock price moves inversely to the broader market with a high degree of volatility, rather than moving in tandem with the S&P 500. This negative beta suggests that the stock behaves as a hedge or counter-cyclical asset in certain market conditions, although such a metric is rare for equity securities.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is also N/A, meaning there is no historical data to compare the rate at which earnings are growing relative to revenue. As a non-dividend payer, Summit Therapeutics has a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company reinvests all available resources into research, development, and commercialization rather than distributing income to shareholders. The absence of dividends is consistent with the company's lifecycle stage, where capital preservation and expansion of the clinical pipeline take precedence over income generation. Overall, the growth and income profile is defined entirely by the potential upside of its lead candidate, ivonescimab, rather than current financial metrics or shareholder returns.